Market
Keros Therapeutics share price at end of Q2 2025?
3
Resolution / Starting Odds
Above $30 • 25%
$20-$30 • 25%
$10-$20 • 25%
Below $10 • 25%
NASDAQ or other financial market data sources
Story
Keros Therapeutics Halts Dosing in Phase 2 PAH Trial Due to Safety Concerns
Dec 12, 2024, 12:02 PM
Keros Therapeutics Inc. (Nasdaq: KROS) has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms of its ongoing Phase 2 TROPOS trial due to safety concerns related to pericardial effusion adverse events. The trial, which evaluates cibotercept (KER-012) in combination with background therapy for patients with pulmonary arterial hypertension (PAH), remains fully enrolled. Dosing in the 1.5 mg/kg treatment arm continues following a risk and benefit assessment by the independent Data Monitoring Committee (DMC). The company has informed investigators and regulatory authorities, including the FDA, of this decision and plans to present topline data from all treatment arms in the second quarter of 2025. Shares of Keros Therapeutics plunged following the announcement.
View original story
Similar markets
Shares increase by up to 50% • 25%
Shares remain stable • 25%
Shares decrease • 25%
Shares increase by over 50% • 25%
Below $1.00 • 25%
Above $2.00 • 25%
$1.51 to $2.00 • 25%
$1.00 to $1.50 • 25%
Decrease • 25%
Increase by 10% or more • 25%
Increase by less than 10% • 25%
No change • 25%
$600 to $700 • 25%
$500 to $600 • 25%
Above $700 • 25%
Below $500 • 25%
Remains within 10% of current price • 25%
Other outcome • 25%
Increases by over 10% • 25%
Decreases by over 10% • 25%
Above $300 • 25%
Below $200 • 25%
$250 to $300 • 25%
$200 to $250 • 25%
No significant change • 25%
Decrease • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Yes • 50%
No • 50%
$100 to $125 • 25%
Above $150 • 25%
$126 to $150 • 25%
Below $100 • 25%
Increase by 10% to 20% • 25%
Remain within ±10% • 25%
Decrease by more than 10% • 25%
Increase by more than 20% • 25%